Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)

16 november 2026 uppdaterad av: Ipsen

QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.

Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.

The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.

Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.

This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.

Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Studietyp

Observationell

Inskrivning (Beräknad)

819

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.

Beskrivning

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

  1. Males ≥18 years old.
  2. Patient with histologically confirmed PCa.
  3. Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
  4. Patient able to understand and complete study-related questionnaires.
  5. Patient having been informed and not opposed to participating in the study.
  6. Patient covered by healthcare insurance.

Exclusion Criteria

Patients will not be included in the study if they meet any of the following criteria:

  1. Patient currently participating in any interventional clinical trial.
  2. Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
  3. Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Tidsram: At 6 months
At 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Participants' baseline demographic characteristics
Tidsram: At baseline

Including:

  • Age.
  • Partnership status.
  • Employment status.
  • Area of residence.
  • Socioeconomic status.
At baseline
Participants' clinical characteristics at baseline
Tidsram: At baseline

Including:

  • BMI
  • Eastern Cooperative Oncology Group (ECOG) Performance status score.
  • G8 score if applicable.
  • Comorbidity status, medical and surgical history, and systemic treatments for comorbidities.
  • Participant's level of physical activity, using IPAQ questionnaire.
At baseline
Prostate cancer characteristics at diagnosis and baseline
Tidsram: At baseline

Including:

  • Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline.
  • Gleason score/International Society of Urological Pathology (ISUP) group
  • TNM (Tumor Node Metastasis) at diagnosis.
  • Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis.
  • Previous treatments received for PCa, if any.
At baseline
Participants symptoms at baseline
Tidsram: At baseline
At baseline
Participants' PCa treatment patterns at baseline
Tidsram: At baseline
  • Triptorelin treatment modalities
  • Radiotherapy modalities
  • Associated systemic PCa treatments
At baseline
Participants' healthcare pathway/supportive care done or planned
Tidsram: At baseline

Including:

  • Pretreatment assessments
  • Visits to supportive health care professionals done or planned.
  • Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals).
  • Associated prescriptions or recommendations
  • Complementary information on cancer patient organizations and/or websites.
At baseline
Evolution of PCa at 6-month follow-up according to investigator's opinion
Tidsram: At 6 months

Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.

At 6 months
Symptoms and biological characteristics at 6 months
Tidsram: At 6 months
At 6 months
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Tidsram: At 6 months

The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.

At 6 months
Participants' Quality Of life (QoL)
Tidsram: At baseline and at 6 months
  • FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline.
  • European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.
At baseline and at 6 months
Participants' PCa treatment patterns at 6 months
Tidsram: At baseline and at 6 months
  • Collection of triptorelin administrations from initiation
  • Radiotherapy modalities in case of changes,
  • Associated systemic PCa treatments in case of changes.
At baseline and at 6 months
Participants' healthcare pathway/supportive care at 6 months
Tidsram: At 6 months

• Participant's healthcare pathway/type of supportive care in case of changes.

At 6 months
Identification of factors associated with participant's quality of life
Tidsram: At 6 months

• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.

At 6 months
Percentage of participants with adverse events
Tidsram: From enrollment to Month 6

An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.

From enrollment to Month 6

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Ipsen Medical Director, Ipsen

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

23 november 2026

Primärt slutförande (Beräknad)

25 februari 2028

Avslutad studie (Beräknad)

30 oktober 2028

Studieregistreringsdatum

Först inskickad

16 november 2026

Först inskickad som uppfyllde QC-kriterierna

16 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Tidsram för IPD-delning

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Kriterier för IPD Sharing Access

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera